Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
29 October 2021Website:
http://www.entradatx.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 02 Jul 2024 20:02:02 GMTDividend
Analysts recommendations
Institutional Ownership
TRDA Latest News
Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a biopharmaceutical company focused on developing innovative medicines that target intracellular pathways previously thought to be unreachable. CEO Dipal Doshi will be speaking at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ in New York City on May 20, 2024 at 9:30 a.m. ET.
Despite providing additional information, the FDA declines to lift the clinical hold on Entrada's (TRDA) regulatory filing seeking approval to start studies on its DMD drug in the United States.
Entrada Therapeutics shares plummeted almost 30% after it announced that the U.S. Food and Drug Administration (FDA) has refused to lift its clinical hold on its Phase 1 study of its investigational therapeutic ENTR-601-44 for Duchenne muscular dystrophy.
Entrada Therapeutics, Inc. (TRDA) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of a loss of $0.55 per share. This compares to loss of $0.80 per share a year ago.
What type of business is Entrada Therapeutics?
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
What sector is Entrada Therapeutics in?
Entrada Therapeutics is in the Healthcare sector
What industry is Entrada Therapeutics in?
Entrada Therapeutics is in the Biotechnology industry
What country is Entrada Therapeutics from?
Entrada Therapeutics is headquartered in United States
When did Entrada Therapeutics go public?
Entrada Therapeutics initial public offering (IPO) was on 29 October 2021
What is Entrada Therapeutics website?
https://www.entradatx.com
Is Entrada Therapeutics in the S&P 500?
No, Entrada Therapeutics is not included in the S&P 500 index
Is Entrada Therapeutics in the NASDAQ 100?
No, Entrada Therapeutics is not included in the NASDAQ 100 index
Is Entrada Therapeutics in the Dow Jones?
No, Entrada Therapeutics is not included in the Dow Jones index
When does Entrada Therapeutics report earnings?
The next expected earnings date for Entrada Therapeutics is 08 August 2024